Royal Bank of Canada’s Orchard Therapeutics plc American Depositary Shares ORTX Stock Holding History

Royal Bank of Canada’s Portfolio ORTX Stock Details ORTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-100	Closed	-$1K	–	7794
2023 Q3	$1K	Buy	100 +30	+43%	+$163	﹤0.01%	6998
2023 Q2	$0	Hold	70	–	–	﹤0.01%	7843
2023 Q1	$0	Buy	70 +69	+6,900%	+$375	﹤0.01%	7667
2022 Q4	$0	Hold	1	–	–	﹤0.01%	7945
2022 Q3	$0	Sell	1 -200	-100%	-$1.11K	﹤0.01%	8049
2022 Q2	$1K	Buy	201 +200	+20,000%	+$1.13K	﹤0.01%	7263
2022 Q1	$0	Hold	1	–	–	﹤0.01%	8140
2021 Q4	$0	Sell	1 -1,079	-100%	-$17.8K	﹤0.01%	8006
2021 Q3	$25K	Buy	1,080 +80	+8%	+$2.38K	﹤0.01%	6588
2021 Q2	$44K	Sell	1,000 -51	-5%	-$2.84K	﹤0.01%	6128
2021 Q1	$77K	Buy	1,051 +51	+5%	+$3.62K	﹤0.01%	5629
2020 Q4	$43K	Buy	1,000 +943	+1,654%	+$42.2K	﹤0.01%	5729
2020 Q3	$2K	Buy	+57	New	+$2.95K	﹤0.01%	6352

Other funds holding ORTX

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BCM

Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

LMR Partners London, United Kingdom $45.4B AUM 60.47% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

GCIA

Gabelli & Co Investment Advisers Rye, New York $674M AUM 64.46% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Royal Bank of Canada's ORTX Position: Q4 2023 in Review

Royal Bank of Canada sold out of Orchard Therapeutics plc American Depositary Shares (ORTX) in Q4 2023, closing a stake of 100 shares — an estimated $1K sold.

Royal Bank of Canada first reported a position in ORTX in Q3 2020 and held it in 13 quarters. The position peaked at $77K in Q1 2021. 47 funds tracked by Wall St. Rank hold ORTX as of Q4 2023.

Royal Bank of Canada reported no remaining Orchard Therapeutics plc American Depositary Shares position as of Q4 2023 after selling out during the quarter.
Royal Bank of Canada sold 100 Orchard Therapeutics plc American Depositary Shares shares in Q4 2023, an estimated $1K.
Royal Bank of Canada first reported a position in Orchard Therapeutics plc American Depositary Shares in Q3 2020 and held it in 13 quarters.
Royal Bank of Canada's Orchard Therapeutics plc American Depositary Shares position peaked at $77K in Q1 2021.
47 funds tracked by Wall St. Rank held Orchard Therapeutics plc American Depositary Shares as of Q4 2023.

Based on Royal Bank of Canada's 13F filing for Q4 2023, filed 14 Feb 2024.